4E-binding proteins, the suppressors of eukaryotic initiation factor 4E, are down-regulated in cells with acquired or intrinsic resistance to rapamycin.
about
Disruption of parallel and converging signaling pathways contributes to the synergistic antitumor effects of simultaneous mTOR and EGFR inhibition in GBM cellsAbnormal growth of smooth muscle-like cells in lymphangioleiomyomatosis: Role for tumor suppressor TSC2Rapamycin is efficacious against primary effusion lymphoma (PEL) cell lines in vivo by inhibiting autocrine signalingExpression of constitutively active 4EBP-1 enhances p27Kip1 expression and inhibits proliferation of MCF7 breast cancer cellsThe inflammatory and normal transcriptome of mouse bladder detrusor and mucosamTOR and cancer therapyDevelopment, characterization, and reversal of acquired resistance to the MEK1 inhibitor selumetinib (AZD6244) in an in vivo model of childhood astrocytoma.Targeting the translational apparatus to improve leukemia therapy: roles of the PI3K/PTEN/Akt/mTOR pathway.Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistance.Resistance to discodermolide, a microtubule-stabilizing agent and senescence inducer, is 4E-BP1-dependent.Catalytic mTOR inhibitors can overcome intrinsic and acquired resistance to allosteric mTOR inhibitors.Initial testing (stage 1) of the investigational mTOR kinase inhibitor MLN0128 by the pediatric preclinical testing programResponse to mTOR inhibition: activity of eIF4E predicts sensitivity in cell lines and acquired changes in eIF4E regulation in breast cancer.Initial testing (stage 1) of the mTOR kinase inhibitor AZD8055 by the pediatric preclinical testing programHigh expression of neuroguidin increases the sensitivity of acute myeloid leukemia cells to chemotherapeutic drugs.The MHC I immunopeptidome conveys to the cell surface an integrative view of cellular regulation.Targeting mTOR/p70S6K/glycolysis signaling pathway restores glucocorticoid sensitivity to 4E-BP1 null Burkitt LymphomaAn essential role for protein synthesis in oncogenic cellular transformation.Targets and mechanisms for the regulation of translation in malignant transformation.Therapeutic potential of target of rapamycin inhibitors.Initiation factor modifications in the preapoptotic phase.mTOR signaling: implications for cancer and anticancer therapy.eIF4E binding protein 1 expression is associated with clinical survival outcomes in colorectal cancerExpression and activity of eIF6 trigger malignant pleural mesothelioma growth in vivo.Predicted mechanisms of resistance to mTOR inhibitors.Investigating mammalian target of rapamycin inhibitors for their anticancer properties.The effect of rapamycin on DNA synthesis in multiple tissues from late gestation fetal and postnatal ratsEnhancing mammalian target of rapamycin (mTOR)-targeted cancer therapy by preventing mTOR/raptor inhibition-initiated, mTOR/rictor-independent Akt activation.PI3K/mTORC1 activation in hamartoma syndromes: therapeutic prospects.Targeting the Mammalian Target of Rapamycin (mTOR) in Cancer Therapy: Lessons from Past and Future PerspectivesModulatory effect of curcumin on survival of irradiated human intestinal microvascular endothelial cells: role of Akt/mTOR and NF-{kappa}B.Therapeutic resistance resulting from mutations in Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR signaling pathways.Mechanisms of mTOR inhibitor resistance in cancer therapy.Translation initiation in colorectal cancer.Adaptation to chronic mTOR inhibition in cancer and in aging.Somatic alterations as the basis for resistance to targeted therapies.ERK and AKT signaling cooperate to translationally regulate survivin expression for metastatic progression of colorectal cancer.Resistance to Targeted Therapies in Renal Cancer: The Importance of Changing the Mechanism of Action.Antiproliferative activity of RAD001 (everolimus) as a single agent and combined with other agents in mantle cell lymphoma.Synergistic growth inhibition by Iressa and Rapamycin is modulated by VHL mutations in renal cell carcinoma.
P2860
Q24550891-3471FDB2-5180-46E6-A2C2-AC9FA94ED902Q24651443-3DC37ED2-96C1-41EE-AF43-C640D969BC19Q24673299-80DBB860-1412-4BF6-8AF1-E97D3046ACC0Q24805438-68ED3EC7-DB4B-4175-B500-589912320959Q25257408-468FE19A-F0CA-4E2D-B805-22CAA016102BQ28268516-6D302F64-6860-453F-B855-97EACA635424Q33861173-2B0D43E6-30FB-4186-B305-2659FCEAB91BQ34173253-DD7E317F-EB86-4679-B704-C13886BBFDEAQ34307356-0E1D18A1-82FA-4B57-8C69-EC3C6344934EQ34471836-49E1706D-B72F-4C23-B31E-61F5EAD6E0EBQ34483665-0BF11997-5D86-4E19-B3F5-1433328DAE38Q34592429-FB2AF54F-872A-4F07-A74F-7E360B6EEDFBQ34660064-018B3858-344C-49C0-90F8-6ECC603CE83CQ35005309-13DCC0C4-6260-4629-969F-809676AE67B4Q35120800-C9BFCE07-7A94-4350-84A7-5DB49A6BD350Q35458694-1185FFA4-DFAB-4386-BA51-2EE463CBBC56Q35696506-6A24FA9C-D8B6-4A46-9556-C49D2C684DD7Q35750105-751547B0-E6E5-4E16-AA91-560A4E815BD2Q35750114-81855026-F677-4F07-A423-7595A7407F80Q35976359-84CD1FB0-87FC-49DA-A118-7012137FAE1DQ36131043-8C8AC744-CC5B-4139-B866-05B5B50FD2CAQ36365093-A0FEB7CE-A7E4-417A-BF72-7FC20075867AQ36414386-BA998633-D3B8-4A41-9D5B-9C3F883EF6E3Q36545784-C718E89E-0B88-409B-BEDB-D6863466BC72Q36585744-902D8014-C4D7-4332-A455-7435ABEB68E6Q36600294-A9531443-BF0B-4A7B-A934-FF7641461073Q36842368-7C1E59B2-362C-487B-8515-49303F67AAADQ36924800-7B572269-4BE6-41C4-8573-C8F31CD34E40Q37032524-BB1241D3-871C-4A12-B2BD-9565B18A9874Q37132788-853C7F1E-7A96-4BB5-8F62-AAB7FE647198Q37174984-F1148F70-AE99-42DA-B86F-155B0E2D6BB0Q37837732-1365ADD3-F2C4-409A-A28E-0C95F57DBFF2Q37872670-7B90117A-70A7-40FB-B7AA-0E92FA1DE03EQ37993753-3A370216-063A-4E9B-9345-D5C74AD63C71Q38122226-AE7A69B3-47EF-4FFB-88E5-4C8EAAD51047Q38151570-B17C298A-88B9-44B3-B8C1-2B580EB6F681Q38532510-558BF9F5-BD37-448A-8BC0-CB2E7158B777Q39008859-07D928F7-B412-4D71-98F6-4A2E5AD5DBC7Q40202733-B0655373-BBEF-41BB-BD2D-FFDC4484C997Q40409431-21A3CBD3-534C-465C-8982-65644F81A39D
P2860
4E-binding proteins, the suppressors of eukaryotic initiation factor 4E, are down-regulated in cells with acquired or intrinsic resistance to rapamycin.
description
2002 nî lūn-bûn
@nan
2002 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
4E-binding proteins, the suppr ...... insic resistance to rapamycin.
@ast
4E-binding proteins, the suppr ...... insic resistance to rapamycin.
@en
4E-binding proteins, the suppr ...... insic resistance to rapamycin.
@nl
type
label
4E-binding proteins, the suppr ...... insic resistance to rapamycin.
@ast
4E-binding proteins, the suppr ...... insic resistance to rapamycin.
@en
4E-binding proteins, the suppr ...... insic resistance to rapamycin.
@nl
prefLabel
4E-binding proteins, the suppr ...... insic resistance to rapamycin.
@ast
4E-binding proteins, the suppr ...... insic resistance to rapamycin.
@en
4E-binding proteins, the suppr ...... insic resistance to rapamycin.
@nl
P2093
P2860
P356
P1476
4E-binding proteins, the suppr ...... insic resistance to rapamycin.
@en
P2093
Arun L Jayaraman
Franklin C Harwood
Glen S Germain
Lorina Dudkin
Michael B Dilling
Peter J Houghton
Xiongwen Zhang
P2860
P304
13907-13917
P356
10.1074/JBC.M110782200
P407
P577
2002-02-14T00:00:00Z